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Theobjectiveofthestudyistoinvestigatetheanti-snakevenomactivitiesofalocalplant, HibiscusaethiopicusL.TheH.aethiopicus
was dried and extracted with ethanol. Diﬀerent assays were performed according to standard techniques, to evaluate the plant’s
acute toxicity and its antivenom activities. The results of evaluating the systemic acute toxicity of the H. aethiopicus extract using
“oral and intra-peritoneal” route were normal even at the highest dose (24g/kg) tested. All guinea pigs (n = 3) when treated with
venoms E.c.sochureki(75µg)aloneinducedacuteskinhaemorrhage.Incontrast,allguineapigs(n = 18)treatedwithbothvenom
and the plant extract at a concentration between 500 and 1000mg/kg showed no signs of haemorrhage. Moreover, all guinea pigs
(n = 18) treated with venom and the plant extract below 400mg/kg showed acute skin haemorrhage. All guinea pigs treated with
venom E. c. sochureki (75µg) alone induced acute skin haemorrhage after both 24 and 32 hours. In contrast, all guinea pigs treated
with both venom and the plant extract (administered independently) at concentrations between 500 and 1000mg/kg showed no
signs of haemorrhage after 32 hours. However, after 24 hours all tested guinea pigs showed less inhibition (<60%) compared to
that obtained after 32 hours. The outcome of this study reﬂects that the extract of H. aethiopicus plant may contain an endogenous
inhibitor of venom induced local haemorrhage.
1.Introduction
Envenoming resulting from snake bites remains the most
neglectedpublichealthissuesinmanycountries,particularly
inpoorruralcommunitieslivinginthetropics.E.c.sochureki
causes numerous deadly bites especially in Asia [1, 2].
Generally envenoming by Echis snake vipers is responsible
for several clinical complications of severe systemic and local
pathology.
Although an intravenous administration of antivenom,
prepared from IgG of venom-immunised horses or sheep,
is an eﬀective treatment for systemic envenoming [3], the
clinicalconsensusisthatantivenomisoflimitedeﬀectiveness
against the eﬀects of local envenoming that develop rapidly
after a bite [4]. Such eﬀects include severe pain, oedema,
localized haemorrhage, and necrosis [5] which often results
in permanent scarring and deformity. The ineﬀectiveness of
antivenom in treating local envenoming has been attributed
to the rapid activity of the toxins and the inability of
antivenom IgG to cross the blood/tissue barrier [6, 7].
Despite their smaller size, F(ab2)2 and Fab fragments of
IgG are also ineﬀective against the local eﬀects of envenom-
ing, whether administered by intravenous or intramuscular
routes [8, 9]. Other limitations of the antivenom(s) also
referred to the variability of snake venom. Venom constitu-
tion within the same snake species can present considerable2 Evidence-Based Complementary and Alternative Medicine
geographical variations [10–12], including a diverse in con-
formity with interpopulational, seasonal, ontogenetic, and
individual factors [13]. Therefore, antivenom made against
venom of an assured species may not be suﬃcient against
envenomation of the same snake species [14]. Research to
develop a treatment for local envenoming against diﬀerent
species as well as among the same species from diﬀerent
areas will be of clinical priority and should focus on the
application of natural [15] or synthetic inhibitors [16]
against snake venom potent molecules. Plant-derived drugs
remain important resource to combat serious diseases. The
present study aims to study the antisnake venom activity of
a local plant, Hibiscus aethiopicus L .w h i c hi sb r o u g h to v e r
200 years ago from Africa and regrown in Bani-Hushash
region, Sana’a Yemen. This plant was found to be used
by traditional healers in Bani-Hushash East of Sana’a to
treat some clinical complications including patients bitten by
snakes and scorpions. Although Hibiscus aethiopicus L. has
longbeenusedasamedicinalplantbytraditionalhealers,the
validity of the claims made for this plant has been previously
tested scientiﬁcally by our research group [17].
2.MaterialsandMethods
2.1. Plant Material. The whole plant of Hibiscus aethiopicus
was collected with assistance of a traditional healer, from
Bani-Hushaiesh. Authentication and the taxonomic identi-
ﬁcation of plant materials was conﬁrmed by Dr. A. Wadieh,
Department of Botany, Naser College, in Lahj Governorate,
University of Aden, Republic of Yemen. One kilogram of
the fresh plant was dried under mild sunshine. The dried
sample was pulverized and stored in plastic bags. A voucher
sample was preserved for reference in the herbarium of the
Pharmacy School, University of Science and Technology,
Sana’a.
2.2. Extraction of Plant Material. The air-dried and pulver-
ized plant (leaves and barks) material (200g) was extracted
with 400mL ethanol (80%, v/v) with continuous shaking
overnight (24 hours). The obtained ethanol extract was
ﬁltered and evaporated using a rotary evaporator and freeze
dryer to give the crude dried extract. The dried extract was
stored at −20◦C until tested.
2.3. Source of Venoms. The venom of E. c. sochureki (India)
used in this study was kindly provided by Mr. P. Rawly, -
The herpetarium, Liverpool School of Tropical Medicine,
Liverpool, UK.
2.4. Ethics Statement. This study was carried out in strict
according to NIH policies outlined in the Guide for Care and
Use of Laboratory Animals. All protocols for animal research
were reviewed and approved by the Animal Research Ethics
Committee (AREC), University of Science and Technology,
School of Medicine and Health Sciences (UST), Sana’a,
Republic of Yemen (no. AREC2009-08-07). For experiment
that involved human plasma an ethics approval from the
Human-Ethics Committee (UST-HEC) of the University of
Science and Technology, School of Medicine and Health
Sciences (UST), Sana’a, Republic of Yemen was obtained in
parallel with a signed consent form from healthy donor (no.
HEC/hs/n01-2009/0813ust).
2.5. Evaluations of Acute Toxicity of H. aethiopicus Extract
In Vivo Using both “Oral” and “Intraperitoneal” Routes.
Two in vivo assays using both “oral” and “intra-peritoneal”
routes were performed to evaluate the acute toxicity and the
cumulative eﬀect “safety protection” potentialities of the H.
aethiopicus composition.
2.6. Oral Route Acute Toxicity. Ten guinea pigs (300–900g)
were used in the toxicity proﬁle. The guinea pigs were
given diﬀerent dosages to investigate the lethal dose. The
extract solution (dissolved in water) was given orally using
anaesthesia at variable dosages to reach 24g/kg above opti-
mum of 16g/kg (a lethal dose according to the international
standardisation for the classiﬁcation of substances). The
animals were observed for behaviour change, continuously
for a period of two weeks after such administration. Obser-
vation was conducted hourly at day 1, and thereafter at
4–6 times per day. Subsequently, blood samples for bio-
chemical analysis, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), complete blood count (CBC), and
gamma glutamyl transpeptidase (GGT) were collected. At
the end of the observation period, animals were sacriﬁced
and dissected. Histopathology examination of their eyes,
liver, lung, and spleen was performed.
2.7. Intraperitoneal Route Acute Toxicity. Eighteen guinea
pigs (300–900g) of both sexes were distributed randomly
into 6 groups (each group of 3 animals) and being treated
i.p. with increasing dosages (250, 500, 750, 1000, 1300, and
1600mg/kg) of H. aethiopicus extract. The ﬁfth group served
as a control and received an equivalent volume of distilled
water. Guinea pigs were observed regularly over a period of
24 hours for signs of acute toxicity and death.
2.8. EvaluationsofH.aethiopicusExtractInVivoforAntisnake
Venom Activity
2.8.1. Administration of both Venom and Extract after Prein-
cubation. Thirty nine adult guinea pigs of both sexes (500–
600g) were divided into 2 groups. Group 1 (of 3 guinea
pigs) was injected with E. c. sochureki venom (75µg/kg)
alone, (dose was previously determined to induce 10±2mm
acute skin haemorrhage). Group 2 was divided into 12 equal
subgroups (G2.1–G2.12) of three guinea pigs each. All of
the subgroups were injected subcutaneously with a mixture
of E. c. sochureki venom and H. aethiopicus extract (50, 75,
100, 200, 300, 400, 500, 600, 700, 800, 900, and 1000mg/kg)
after both venom and extract were incubated in a test tube
for 30 minutes. All animals were observed over 24 hours. At
the end of the observation period, animals were sacriﬁced,
and their skins were dissected to examine the haemorrhage
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2.8.2. Administration of Extracts 3 Hours Prior to Venom
Injection. Twenty eight adult guinea pigs of both sexes (500–
600g) were divided into 2 groups. Group 1 (of 4 guinea
pigs) was injected with E. c. suchorecki venom (75µg/kg,
subcutaneously) alone. Group 2 was divided into 6 equal
subgroups (G2.1–G2.6) of four guinea pigs each. All of
the subgroups were injected subcutaneously with the same
dose (75µg/kg, subcutaneously) of E. c. sochureki venom
30 minutes after H. aethiopicus extract was administered
orally by gastric intubation at diﬀerent concentrations (100,
200, 300, 500, 800, and 1000mg/kg). Animals (14 at each
interval time) were sacriﬁced, and their skins were dissected
to examine the neutralisation eﬃcacy of the extract after 24
and 32 hours, respectively.
2.9. Coagulant Activity. The plasma coagulation property
was determined according to the method of Theakston and
Reid (1983) [18] with minor modiﬁcation. Brieﬂy normal
healthy human-citrated plasma 200µL (preincubated at
37◦C) was incubated with 75µg of venom sample (dissolved
in 50µL PBS, pH 7.2), and the clotting time was recorded
against a light source. For inhibition examination, the
venom sample was preincubated with the extract at diﬀerent
concentrations (i.e., 100, 200, 400, 500, and 1000mg).
2.10. Oedema-Inducing Activity. The oedema-inducing
activity was assayed according to the method of Vishwanath
et al., (1987) [19] with minor modiﬁcation. Group 1
of 3 guinea pigs was injected in the right footpads with
3x minimum oedema dose (MED) (7.5µg, previously
determined) of venom sample (dissolved in 20µL PBS, pH
7.2). The left footpads received saline, as controls. Legs were
cut oﬀ at the ankle joint after 6 hours. An increase in weight
due to oedema was calculated as the oedema ratio, which
equals the weight of the oedematous leg × 100/weight of
control leg. The MED was deﬁned as the amount of venom
sample required to cause an oedema of 100%. Group 2 (for
inhibition examination) was divided into 8 equal subgroups
(3 guinea pig in each) were injected subcutaneously with
the venom sample that was preincubated with the extract
at diﬀerent concentrations (37.5–525µg) for 30 minutes at
37◦C.
3. Results
3.1. Administration of H. aethiopicus via “Oral and Intra
Peritonial” Routes Has no Acute Toxic Eﬀect. All animals
were alive after the 2 weeks of given 24g/kg extract solution
above the lethal dosage of 16g/Kg. No abnormal behaviour
was observed. Animals showed normal body weight increase
during the two weeks period. Biochemical analysis showed
normal range of ALT, AST, CBC, and GGT (Table 1).
Inspection of the eyes, liver, lung, and spleen showed
no extraordinary signs. The results when compared to a
general acute toxicity index were normal, and no acute
toxicity was observed. Furthermore, guinea pigs dosed intra-
peritoneally with H. aethiopicus extract were initially dull
with signiﬁcantly reduced movement for 20–30 minutes.
However, neither death nor signs of toxicity were observed
even at the highest dose (24g/kg) tested.
3.2. Preincubation of H. aethiopicus Inhibits Venom-Induced
Haemorrhage. All guinea pigs treated (injected subcuta-
neously) with venoms E. c. sochureki (75µg) alone “Group
1” (n = 3) induced 10 ± 2mm acute skin haemorrhage
(Figure 1(A), a). In contrast, all guinea pigs “Group 2”
(n = 18) treated with both venom and the plant extract
at concentrations between 500mg/kg (Figure 1(A), f) and
1000mg/kg (Figure 1(A), k) showed no signs of acute skin
haemorrhage(P<0.002)(Figure 1(B)).Moreover,allguinea
pigs(n = 18)treatedwithvenomandtheplantextractbelow
500mg/kg showed acute haemorrhage similar to the controls
(Figure 1(A), b–e).
3.3. Oral Administration of H. aethiopicus Prior to Venom
Injection Inhibits Haemorrhage Induction. All guinea pigs
treated (n = 4) with venoms E. c. sochureki (75µg) alone
“Group 1” induced acute skin haemorrhage (10mm) after
both 24 (Figure 2(A), a) and 32 hours (Figure 2(A), a1)
of skin dissection. In contrast, all guinea pigs “Group 2
(n = 6)” treated with both venom and the plant extract
at concentrations of 500, 800, and 1000mg/kg showed no
signs of acute skin haemorrhage after 32 hours (P ≤ 0.0001)
(Figure 2(A),b1–d1andFigure 2(B))aP<0.0001.However,
after 24 hours (Figure 2(A), b–d), all 6 animals showed
similar haemorrhage pattern with the control (Figure 2(B),
a1) and (Figure 2(B)) a P value of 0.001. All guinea pigs
treated with venom and the plant extract below 500mg/kg
showed acute haemorrhage (n = 12), regardless of the time
the skin dissection was taken (data not shown).
3.4. The H. aethiopicus Extract Inhibits Venom Coagulation
Activity. The extract was found to inhibit, dose dependently,
the procoagulant activity of the E. c. sochureki venom
(Figure 3). A progressive increased clotting time resulting in
anticoagulation was recorded (Figure 3). The anticoagulant
responsereachedanoptimumwithaclottingtimeof600±4,
and this was attained at the extract concentration of 500mg
(P<0.0001).Nosigniﬁcantdiﬀerencewasobservedbetween
both concentration of 500 and 1000mg as both gave the
same anticoagulant response. In contrast, in the absence of
the extract, the control value containing the venom sample
alone revealed a clotting time of 28 ± 3s (P ≤ 0.0001).
However, when induced with Ca+2 alone, clot formation was
seen at 325 ± 4s (data not shown).
3.5. The H. aethiopicus Extract Inhibits Oedema Induction.
Toxicitystudiesinamousemodelrevealedthefollowing.The
MED was found to be 7.5µg (this is the amount of venom
sample required to cause an oedema of 100%). The 3x MED
found to cause an oedema of 190 ±2%. The venom-induced
haemorrhagic oedema was also inhibited dose dependently
by the extract. At a ratio of venom to extract of 1:60 and
1:70 (w/w), the oedema of 190 ± 2.0% (caused due to 3x
M E Do fv e n o m )w a sr e d u c e dt o1 2 0± 2.0% which is the
same as the control (i.e., leg injected with PBS), (P<0.0001)4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (A) Dissected skins of guinea pigs showing dose dependent of antivenom neutralisation eﬃcacy of H. aethiopicus extract. (a)
Control: animals were injected with 75µgo fE. c. sochureki alone. (b–k) represent diﬀerent concentration (100–1000mg/kg) of the H.
aethiopicus extract. (f) represents the optimum concentration (500mg/kg) of the H. aethiopicus e x t r a c tt h a tg i v e sac o m p l e t ev e n o m
neutralisation after both venom and extract were incubated in a test tube for 30 minutes. (B) Response curve showing dose dependent
of antivenom neutralisation eﬃcacy of H. aethiopicus extract. Neutralisation eﬃcacy of diﬀerent concentrations (100–1000mg/kg) of the H.
aethiopicus extract preincubated in a test tube for 30 minutes with ﬁxed concentration of the E. c. sochureki venom. Chart illustrates the end
point concentration (i.e., 400) where no adequate haemorrhage pattern found to be measured. ∗∗P<0.01 and ∗∗∗P<0.0001.
(i.e., the foot pad that was injected with the saline alone)
(Figure 4).
4. Discussion
Plants constitute rich sources of novel compounds with a
variety of pharmacological activities. Therefore, experimen-
talvalidationofthetraditionaluseofplantsisimportant and
can facilitate the development of low-cost phytotherapeutic
agents [9]. Plants used as remedy for snakebite abound in
literature [20–23]. However, many of the reported studies
lack detailed scientiﬁc investigation, which is needed in the
development of medicinal agents from plants [20–22].
In this study we have used H. aethiopicus, one of the
main traditional herbal plants which is used as phytotherapy
practiced by a large proportion of the Yemen population
for the treatment of several clinical complications including
snake envenomation. To our knowledge no scientiﬁc reports
on H. aethiopicus and its capacity to neutralise snake
venom(s) available except a single study that was publishedEvidence-Based Complementary and Alternative Medicine 5
Table 1: Biochemical analysis for acute toxicity of the H. aethiopicus plant.
Group (G) ALT (Mean∗) AST (Mean∗) GGT (Mean∗)
G1: Normal (n = 4) 49 ±3.6∗ 109 ±2.13 .2 ±1
G2: Intoxicated control (n = 4) 81 ±1.8 197 ±4.13 .6 ±0.2
G4: Guinea pigs (n = 10) 51 ±3.2 111 ±1.33 .4 ±0.9
ALT: alanine aminotransferase.
AST: aspartate aminotransferase.
GGT: gamma glutamyl transpeptidase.
Data are expressed as International Units (IU/mL); ∗Mean value signiﬁcantly diﬀerent (P<0.05) compared with respective values (before treatment) using
paired Student’s t-test. n: number of animal (guinea pigs). ∗All values presented are means ± SE (standard error). No statistically signiﬁcant diﬀerences were
observed.
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Figure 2: (A) Dissected skins of guinea pigs showing oral administrations of the H. aethiopicus extract three hours prior to venom injection
(a) control where animals were injected with 75µgo fE. c. sochureki alone; (b, c, and d) represent diﬀerent concentrations (500, 800,
and 1000mg/kg), respectively, of the H. aethiopicus extract that was orally administered 3 hours prior to venom injection, and animals
were sacriﬁced after 24 hours to examine their skins; (a1 to d1) are the same of the above except that animals where sacriﬁced and skins
where dissected after 32 hours. (B) Chart showing oral administrations of the H. aethiopicus extract three hours prior to venom injection.
Neutralisation eﬃcacyofdiﬀerentconcentrationsoftheH.aethiopicusextractwhenadministeredorallythreehourspriortovenominjection
(75µg). The grey and black lines illustrate the gradual neutralisation eﬃcacy of the extract correlated to diﬀerent concentrations after 24 and
32 hours results, respectively, of animal dissected. ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.0001.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Inhibition of procoagulant activity. Fixed dose of
E. c. sochureki venom (75µg) was preincubated with variable
concentration of the extract at 37◦C for 30min. Then, 100µLo f
the mixture was added to 200µL of citrated human plasma and
the coagulation time was determined. The inset shows the dose-
dependentprocoagulantactivityofE.c.sochurekivenomoncitrated
healthy human plasma. ∗∗∗P<0.0001.
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Figure 4: Response curve of dose dependent of oedema neutraliza-
tion. Experiments were performed by preincubating 37.5–525µgo f
extractandﬁxeddoses(7.5µg)ofE.c.sochurekivenomfor30minat
37◦C( s e eSection 2). Dotted line represents the control, that is, the
foot pad that received a saline only. Data are represented as mean ±
SEM (n = 3).
by our research group [17]. Therefore, this study represents
the second report about H. aethiopicus and its uses as
antivenom agent against E. c. sochureki.
In contrast to our results reported in the previous
work [17], the oral route when compared to a general
acute toxicity index showed normal with no extraordinary
symptoms as well as no acute toxicity. However, both routes
showed no death even at the highest tested dose (24mg/kg)
compared to the previous work. This was supported further
by the biochemical analysis as shown in Table 1.H o w e v e r ,
with intra-peritoneal route doses, guinea pigs were initially
dull with signiﬁcantly reduced movement for about 20–30
minutes (P<0.005).
InthesubsequentexperimentsweusedtheH.aethiopicus
extract to assess its eﬃcacy to neutralise the haemorrhagic
activity of E. c. sochureki venom using an in vivo minimum
haemorrhagic dose (MHD). It was interesting to note
that results of the evaluation assays of antisnake venom
activity showed that H. aethiopicus induced noticeable and
signiﬁcant neutralisation capacity against venom of E. c.
sochureki. This was clearly illustrated in Figure 1(A), a–k. In
a guinea pig animal model, MHD was found to be 25µg,
and the 3x MED was found to cause the skin haemorrhagic
area of 10 ± 2mm. It can be seen from (Figure 1(A), e)
that at concentration of 400mg/kg which act as the end
point (Figure 1(B)) showed a slight haemorrhage and/or
inﬂammation. Therefore, above, that is, 400mg/kg, neutral-
isation eﬃcacy of 100% was achieved at a concentration of
500mg/kg (Figure 1(A), f).
Results from the oral administration of the extract 3
hours prior to venom injection were signiﬁcant and showed
future promising (Figure 2(A)). In this assay we examined
the neutralisation eﬃcacy of the extract using two prospects
based on time intervals of 16 and 32 hours, respectively.
In comparison with the results from above we have
found that the concentration that gave 100% neutralisation
was 1000mg/kg after 32 hours rather than after 16 hours,
suggesting that this diﬀerence is due to the time needed for
the absorption and distribution of the active components in
H. aethiopicus extract. Although such comparison between
the two assays is not adequate as in the ﬁrst assay, a close
contactbetweentheextractandvenomwasachievedtogivea
maximal neutralizing eﬀect. Therefore, further investigation
of the absorption rate should be performed. Moreover,
this result can also suggest that having the extract before
envenomation can act as a prophylactic agent.
Ecarin is an extensively characterized metalloprotease
present in E. c. sochureki venom and has been found to acti-
vate prothrombin directly resulting in the pro-coagulation
of citrated human plasma [24]. This property of E. c.
sochureki procoagulant was found to be independent of
Ca+2 requirements [25, 26]. In addition, ecarin also cleaved
human ﬁbrinogen and dissolved the ﬁbrin clot [27]. The
prothrombin converting and ﬁbrinogenolytic (thrombin-
like) activity of ecarin appears to be responsible for the
procoagulant activity of the venom. Interestingly in this
study we found that the extract can inhibit dose dependently
the procoagulant activity of the E. c. sochureki venom and
progressively increases clotting time resulting in anticoag-
ulation (Figure 2(A)). The anticoagulant response of the
extract reached an optimum with a clotting time of 600 ±
4s, and this was attained at the extract’s concentration of
400mg (P<0.0001). However, no signiﬁcant diﬀerence
between both concentrations of 500 and 1000mg was found
as both gave the same anticoagulant response. In contrast,
in the absence of the extract, the control value containing
the venom sample alone revealed a progressively decreasing
clotting time which reached an optimum at 28 ± 3s for a
venom concentration of (75µg) of the venom sample, (P<
0.0001) (Figure 3). However, when induced with Ca+2 alone,Evidence-Based Complementary and Alternative Medicine 7
clot formation was seen at 321± 4s (data not shown). Since
ecarin appears to be the principal procoagulant agent of E.
c. sochureki venom, the extract might induce the inactivation
of ecarin. This was conﬁrmed by early studies where several
anticoagulants have been isolated and studied extensively
from this venom [24, 28–31]. In addition to the coagulation
assay, we examined the neutralisation of the extract against
the oedema inducing activity of the E. c. sochureki venom.
The result was signiﬁcant, and the extract was found to
inhibit dose dependently the venom-induced haemorrhagic
o e d e m a .A tar a t i oo fv e n o mt oe x t r a c to f1:6 0a n d1:7 0
(w/w), the oedema of 190 ± 2.0% (caused due to 3x MED
of venom) was reduced to 120 ± 2.0% which is the same as
the control (i.e., the foot pad that was injected with the saline
alone) (Figure 4), (P ≤ 0.0001). In several experimental and
clinical trials, it has been demonstrated that antivenoms are
of limited value to stop oedema progression within the ﬁrst
12–24 hours of treatment, while they are highly eﬃcient
in restoring blood coagulation status within the same time
interval [32–34]. Moreover, the rapid neutralization of
venom in the bloodstream does not guarantee the halting
of oedema progression within a short time. Therefore, in
this study, we report for ﬁrst time that the extract of the H.
aethiopicus showed high neutralizing potency against such
eﬀect within six hours of venom injection. However, this
ﬁnding was based on in vitro testing, (i.e., close contact
between the extract and venom). Therefore, to conﬁrm such
eﬃcacy, an in vivo assay has yet to be performed where, the
extract has to be given orally “independent,” that is, before
and/or after the venom being injected.
Despite these protective eﬀects of the plant extract of
the H. aethiopicus in vitro, the results obtained from the in
vivo experiment (Figure 2(A)) were highly encouraging. The
extract did protect animals challenged with local haemor-
rhage of the E. c. sochureki venom when the extract and
venom were administered independently. However, haem-
orrhage induction was signiﬁcantly reduced (P<0.0001)
and or fully neutralised with the increase of the extract
concentration and time, in contrast with the preincubation
assay represented by Figure 1.
The outcome of this study reﬂects that the extract of
H. aethiopicus plant may contain an endogenous inhibitor
of venom-induced local haemorrhage. This obviously would
need further investigations for both systemic and local eval-
uation. Further studies on the fractionation(s), isolation and
characterization of the active principle/s, and its antivenom
property appears promising and could contribute to the
development of a potent and perhaps safe antidote against
E. c. sochureki venom poisoning and might play a role in the
better management of the threatening lethal bites.
5. Summary
Snake bite remains a public health problem in many
countries even though; it is diﬃcult to be precise about
the actual number of cases. It is estimated that the true
incidence of snake envenomation could exceed 5 million
per year and causing about 125,000 deaths each year,
predominantlywithinpoorcommunitieslivinginruralareas
of countries in Southeast Asia and Africa. Although an
intravenous administration of antivenom, prepared from
IgG of venomimmunised horses or sheep, is an eﬀective
treatment for systemic envenoming, the clinical consensus is
that antivenom is of limited eﬀectiveness against the eﬀects
of local envenoming that develop rapidly after a bite. In
addition to its high cost and other limited eﬀectiveness, thus,
there is a need to develop novel therapeutics to maximise the
utility of the snakebite therapies that are available. Research
to develop a treatment for local envenoming is therefore a
clinicalpriorityandhasfocusedontheapplicationofnatural
orsyntheticinhibitorsofsnakevenompotentmolecules.The
traditional medicine to treat snakebite victims still plays an
important role in the primary health care worldwide, espe-
cially in rural areas and poor communities in the third world
countries is a common practice. Because natural products
of higher plants may give a new source of medication, there
are many research groups that are now engaged in medicinal
plants research not only for the discovery for new drugs, but
possibly for discovering compounds with novel mechanisms
ofactionthatcanstimulatenewﬁeldsofresearch.Ourresults
suggest that that Hibiscus aethiopicus L. plant may contain an
endogenous inhibitor of venom-induced haemorrhage.
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